BioSpace News Archive

NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases, today announced statistically significant and clinically robust LDL-c lowering results in its recently completed Phase 2 clinical study evaluating oral obicetrapib, an investigational novel selective cholesteryl ester transfer protein (CETP) inhibitor.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the full fiscal year 2021 ended April 30, 2021.

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter ended June 30, 2021, after the US markets close on Monday, August 9, 2021.

Bridge Medicines and Cornell University announced an exclusive license agreement to develop UBR5 Inhibitors for the treatment of certain difficult-to-treat cancers such as triple-negative breast cancer.

Novian Health Inc., a clinical stage medical device company focused on the development of image-guided laser therapy for the focal destruction of malignant and benign breast tumors, announced the first closing of a private placement financing, raising total proceeds of over $5 million.

Galaxy Medical announced today that the ECLIPSE-AF 90-day remapping data, presented at the Stanford BioDesign New Arrhythmia Technologies retreat, demonstrated durable lesions and chronic pulmonary vein isolation (PVI).

THREAD, a technology and service provider enabling decentralized clinical trials (DCTs), and Almac Clinical Technologies, a member of the contract and development organization, Almac Group, today announced a strategic partnership.

Kriya Therapeutics, Inc., a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, today announced the completion of the renovation of its 51,000 square foot facility located in Research Triangle Park, North Carolina to support cGMP production of its expanding pipeline of gene therapies.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.

Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the availability of AirLife™ Open oxygen mask, a revolutionary new low-flow oxygen therapy device designed to advance the standard of care and improve the satisfaction of patients receiving low-flow oxygen therapy.